Wechselwirkungen · Emtriva
Emtriva 10 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 18
HOS-112708 · Präparat HOS-093727
Emtricitabine is primarily excreted via glomerular filtration and active tubular secretion. With the exception of famciclovir and tenofovir disoproxil fumarate, the effect of co-administration of emtricitabine with medicinal products that are excreted by the renal route, or other medicinal products known to affect renal function, has not been evaluated. Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may lead to an increase in serum concentrations of either emtricitabine or a co-administered medicinal product due to competition for this elimination pathway.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): famciclovir (HOS-112681) lead (HOS-085592) tenofovir disoproxil fumarate (HOS-110471)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-04-18T12:34:00Z · SHA-256 4ee4f99346bca4db5449cf522784d6dbc4cba891b89d833a052a1c777428bfcb · Passage 1f86794a3dc59253f5b34c61d143b3ec5f5ca3b0e639810b008adb83d8da8620 · Zeichen 664–1286 im Abschnitt